Vertex posts strong Q2 on robust Trikafta sales

Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 results:

Total product sales: $1,524M (+62.1%); Trikafta: $918M; Orakambi: $232M (-26.6%); Kalydeco: $203M (-22.5%); Symdeko/Symkevi: $172M (-52.5%).

Net income: $837M (+213.5%); non-GAAP net income: $687M (+110.1%); EPS: $3.18 (+208.7%); non-GAAP EPS: $2.61 (+107.1%).

2020 guidance: Product sales: $5.7B – 5.9B from $5.3B – 5.6B.

https://seekingalpha.com/news/3598073-vertex-posts-strong-q2-on-robust-trikafta-sales